FY2029 Earnings Estimate for Aemetis Issued By HC Wainwright

Key Points

• HC Wainwright has revised Aemetis' FY2029 earnings estimate down from $4.23 to $4.22 per share, while the current consensus estimate for full-year earnings is a loss of ($2.07) per share.
• Aemetis' stock price saw a significant increase of 10.3%, with shares opening at $2.67 on Monday amidst fluctuating market conditions.
• Institutional investors are increasing their stakes in Aemetis, with notable raises from Clear Harbor Asset Management and Vanguard Personalized Indexing Management, improving overall institutional ownership to 27.02%.

Aemetis, Inc (NASDAQ:AMTX - Free Report) - Equities researchers at HC Wainwright decreased their FY2029 EPS estimates for shares of Aemetis in a research report issued to clients and investors on Friday, August 8th. HC Wainwright analyst A. Dayal now anticipates that the specialty chemicals company will post earnings of $4.22 per share for the year, down from their previous estimate of $4.23. The consensus estimate for Aemetis' current full-year earnings is ($2.07) per share.

AMTX has been the subject of several other research reports. UBS Group boosted their price objective on shares of Aemetis from $2.20 to $3.00 and gave the stock a "buy" rating in a research note on Monday, June 30th. Ascendiant Capital Markets boosted their price objective on shares of Aemetis from $19.00 to $20.00 and gave the stock a "buy" rating in a research note on Friday, June 6th.

Aemetis Stock Up 0.9%

Shares of NASDAQ AMTX traded up $0.03 during trading hours on Monday, hitting $2.68. 241,545 shares of the stock were exchanged, compared to its average volume of 960,056. The company has a market cap of $169.17 million, a PE ratio of -1.66 and a beta of 1.49. The firm has a fifty day moving average price of $2.65 and a 200-day moving average price of $2.05. Aemetis has a 12 month low of $1.22 and a 12 month high of $4.73.

Aemetis (NASDAQ:AMTX - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The specialty chemicals company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.06). The firm had revenue of $52.24 million for the quarter, compared to analyst estimates of $78.68 million.

Institutional Investors Weigh In On Aemetis

A number of large investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. increased its position in shares of Aemetis by 515.9% in the 4th quarter. JPMorgan Chase & Co. now owns 120,716 shares of the specialty chemicals company's stock valued at $325,000 after acquiring an additional 101,116 shares during the period. Geode Capital Management LLC increased its position in shares of Aemetis by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 934,993 shares of the specialty chemicals company's stock valued at $2,516,000 after acquiring an additional 10,700 shares during the period. Wells Fargo & Company MN increased its position in shares of Aemetis by 20.0% in the 4th quarter. Wells Fargo & Company MN now owns 45,741 shares of the specialty chemicals company's stock valued at $123,000 after acquiring an additional 7,622 shares during the period. Russell Investments Group Ltd. increased its position in shares of Aemetis by 684.5% in the 4th quarter. Russell Investments Group Ltd. now owns 78,191 shares of the specialty chemicals company's stock valued at $210,000 after acquiring an additional 68,224 shares during the period. Finally, Renaissance Technologies LLC acquired a new position in shares of Aemetis in the 4th quarter valued at $203,000. 27.02% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Aemetis news, Director Francis P. Barton sold 26,452 shares of the company's stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $2.53, for a total transaction of $66,923.56. Following the transaction, the director owned 208,518 shares in the company, valued at approximately $527,550.54. This represents a 11.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 14.70% of the company's stock.

About Aemetis

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.